|Description||ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing. ETP-46321 PK/PD studies showed time dependent downregulation of AKT(Ser473) phosphorylation, which correlates with compound levels in tumor tissue and demonstrating to be efficacious in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation. Treatment with ETP-46321 resulted in significant tumor growth inhibition.|
|B0084-462342||300 mg||$499||In stock|
|Current Developer||Spanish National Cancer Research Centre (CNIO), Madrid, Spain.|
PIK-93 is a potent PI3K inhibitor.
LTURM 36 is a PI3-kinase δ inhibitor with IC50 value of 0.64μM. It shows anticancer activity in a renal cancer cell line.
SAR-405 is a potent and selective inhibitor of phosphoinositide 3-kinase (PI3K) class III isoform Vps34 (IC50= 1.2 nM, Kd= 1.5 nM) without disrupting other PI3K...
TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which is approximately 1000 -fold selective over alpha isoform, >30-...
CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...
SF2523 is a dual inhibitor of phosphatidylinositol 3-kinase and bromodomain-containing protein 4 with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for ...
GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials....
AZD-8835 was selected as a clinical candidate for the treatment of PIK3CA-dependent cancers and is currently in phase I clinical trials. It is an orally bioavai...
AS 252424 bispotassium salt is the potassium salt form of AS 252424, which is a potent and selective PI3K p110γ inhibitor.
AS-604850 is a selective, ATP-competitive PI3Kγ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3Kγ than PI3Kδ/β, and 18-fold more selective for P...
BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...
MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.
TG100-115 is a potent and selective PI3K γ and -δ inhibitor (IC50 values of 83 and 235 nM, respectively) with no effect on PI3Kα or -β (IC50 values > 1 μM). As ...
Vps34-PIK-III is a potent and selective inhibitor of the type 3 phosphatidylinositol 3-kinase (PI3K) vacuolar protein sorting 34 (Vps34) (IC50= 18 nM). Vps34-PI...
Copanlisib hydrochloride is a potent inhibitor of Class I phosphoinositide 3-kinase which showed a therapeutic effect on non-Hodgkin lymphoma. It was approved t...
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...
AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. Phase 1.
PI 828 is a cell permeable 4′-amino derivative which inhibits the p110α, p110β, p110δ, and p110γ subunits of PI 3-kinase. PI-828 is a potent inhibitor of phosph...
XL 765 is a PI3K inhibitor used for the treatment of cancers. It also suppresses DNA-PK and mTOR.
Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor...